Imunon Inc (NASDAQ:IMNN) — Market Cap & Net Worth
Market Cap & Net Worth: Imunon Inc (IMNN)
Imunon Inc (NASDAQ:IMNN) has a market capitalization of $7.74 Million ($7.74 Million) as of September 18, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #27775 globally and #5722 in its home market, demonstrating a -8.61% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Imunon Inc's stock price $1.38 by its total outstanding shares 5611403 (5.61 Million). Also see Imunon Inc (IMNN) total assets for a full breakdown of the balance sheet.
Imunon Inc Market Cap History: 2015 to 2026
Imunon Inc's market capitalization history from 2015 to 2026. Data shows change from $2.26 Billion to $7.74 Million (-40.57% CAGR). Also see IMNN cash generation efficiency for how efficiently the company converts equity into cash flow.
Index Memberships
Imunon Inc is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.67 Trillion | 0.00% | #798 of 976 |
|
NASDAQ Composite
IXIC
|
$41.95 Trillion | 0.00% | #2564 of 3165 |
Weight: Imunon Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Imunon Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Imunon Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check current stock price of Imunon Inc for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
30.53x
Imunon Inc's market cap is 30.53 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $353.52 Million | $500.00K | -$22.05 Million | 707.04x | N/A |
| 2017 | $225.58 Million | $500.00K | -$20.40 Million | 451.16x | N/A |
| 2018 | $118.68 Million | $500.00K | -$11.88 Million | 237.36x | N/A |
| 2019 | $143.93 Million | $500.00K | -$16.85 Million | 287.86x | N/A |
| 2020 | $59.76 Million | $500.00K | -$21.48 Million | 119.52x | N/A |
| 2021 | $45.45 Million | $500.00K | -$20.77 Million | 90.90x | N/A |
| 2022 | $7.58 Million | $500.00K | -$35.90 Million | 15.15x | N/A |
| 2023 | $3.82 Million | $125.00K | -$19.51 Million | 30.53x | N/A |
Competitor Companies of IMNN by Market Capitalization
Companies near Imunon Inc in the global market cap rankings as of September 18, 2026. Review Imunon Inc (IMNN) tangible equity ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Imunon Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #185 globally with a market cap of $130.87 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #337 globally with a market cap of $79.84 Billion USD.
- CSL Ltd (AU:CSL): Ranked #455 globally with a market cap of $60.95 Billion USD ( AU$86.14 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #504 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #185 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.87 Billion | $516.34 |
| #337 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $79.84 Billion | $789.45 |
| #455 | CSL Ltd | AU:CSL | $60.95 Billion | AU$177.56 |
| #504 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $158.07 |
Imunon Inc Historical Marketcap From 2015 to 2026
Between 2015 and today, Imunon Inc's market cap moved from $2.26 Billion to $ 7.74 Million, with a yearly change of -40.57%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $7.74 Million | -63.78% |
| 2025 | $21.38 Million | +301.05% |
| 2024 | $5.33 Million | +39.71% |
| 2023 | $3.82 Million | -49.63% |
| 2022 | $7.58 Million | -83.33% |
| 2021 | $45.45 Million | -23.94% |
| 2020 | $59.76 Million | -58.48% |
| 2019 | $143.93 Million | +21.28% |
| 2018 | $118.68 Million | -47.39% |
| 2017 | $225.58 Million | -36.19% |
| 2016 | $353.52 Million | -84.38% |
| 2015 | $2.26 Billion | -- |
End of Day Market Cap According to Different Sources
On Sep 18th, 2026 the market cap of Imunon Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $7.74 Million USD |
| MoneyControl | $7.74 Million USD |
| MarketWatch | $7.74 Million USD |
| marketcap.company | $7.74 Million USD |
| Reuters | $7.74 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Imunon Inc
Imunon, Inc., a clinical-stage biotechnology company, focuses on developing immunotherapies and vaccines in the United States. The company's lead clinical program is IMNN-001, a DNA-based immunotherapy that is in a Phase 3 clinical trial for the localized treatment of advanced ovarian cancer, as well as in the IND-enabling phase for colorectal and pancreatic cancers, and in the discovery phase fo… Read more